These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30149880)

  • 1. Protein-Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway.
    García-Gómez R; Bustelo XR; Crespo P
    Trends Cancer; 2018 Sep; 4(9):616-633. PubMed ID: 30149880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to MEK inhibitors: should we co-target upstream?
    Poulikakos PI; Solit DB
    Sci Signal; 2011 Mar; 4(166):pe16. PubMed ID: 21447797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
    Friday BB; Adjei AA
    Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ; Der CJ
    Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEK in cancer and cancer therapy.
    Neuzillet C; Tijeras-Raballand A; de Mestier L; Cros J; Faivre S; Raymond E
    Pharmacol Ther; 2014 Feb; 141(2):160-71. PubMed ID: 24121058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1Alpha,25-dihydroxyvitamin D3-mediated stimulation of steroid sulphatase activity in myeloid leukaemic cell lines requires VDRnuc-mediated activation of the RAS/RAF/ERK-MAP kinase signalling pathway.
    Hughes PJ; Brown G
    J Cell Biochem; 2006 Jun; 98(3):590-617. PubMed ID: 16440327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting RAS-ERK signalling in cancer: promises and challenges.
    Samatar AA; Poulikakos PI
    Nat Rev Drug Discov; 2014 Dec; 13(12):928-42. PubMed ID: 25435214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Roles of targeting Ras/Raf/MEK/ERK signaling pathways in the treatment of esophageal carcinoma].
    Chang YS; Liu JC; Fu HQ; Yu BT; Zou SB; Wu QC; Wan L
    Yao Xue Xue Bao; 2013 May; 48(5):635-41. PubMed ID: 23888683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes.
    Eblen ST
    Adv Cancer Res; 2018; 138():99-142. PubMed ID: 29551131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
    Asati V; Mahapatra DK; Bharti SK
    Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells.
    Noser JA; Mael AA; Sakuma R; Ohmine S; Marcato P; Lee PW; Ikeda Y
    Mol Ther; 2007 Aug; 15(8):1531-6. PubMed ID: 17505473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
    Komatsu N; Fujita Y; Matsuda M; Aoki K
    Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management.
    Manousaridis I; Mavridou S; Goerdt S; Leverkus M; Utikal J
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):11-8. PubMed ID: 22540151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases.
    Pan MR; Chang HC; Hung WC
    Cell Signal; 2008 Jun; 20(6):1134-41. PubMed ID: 18374541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic Ras pushes (and pulls) cell cycle progression through ERK activation.
    Campbell PM
    Methods Mol Biol; 2014; 1170():155-63. PubMed ID: 24906314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.
    Zhang Q; Wei L; Yang H; Yang W; Yang Q; Zhang Z; Wu K; Wu J
    Cancer Lett; 2016 Feb; 371(1):107-16. PubMed ID: 26620707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer.
    Sharma SB; Ruppert JM
    Drug Dev Res; 2015 Sep; 76(6):328-42. PubMed ID: 26284568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear ERK: Mechanism of Translocation, Substrates, and Role in Cancer.
    Maik-Rachline G; Hacohen-Lev-Ran A; Seger R
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30857244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coordinating ERK/MAPK signalling through scaffolds and inhibitors.
    Kolch W
    Nat Rev Mol Cell Biol; 2005 Nov; 6(11):827-37. PubMed ID: 16227978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.